All In Biotech

Free tool

FAERS Monitor: Alecensa

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208434 or its brand name (Alecensa, Alectinib Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

7,388

Serious

4,065

55% of reports

Hospitalization

1,310

Death reported

951

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death718
  • fatigue526
  • no adverse event472
  • off label use472
  • constipation455
  • rash267
  • dyspnoea240
  • disease progression216
  • weight increased213
  • myalgia212
  • asthenia200
  • peripheral swelling180
  • drug ineffective173
  • nausea167
  • pain163

Reports by year received

View as table
YearReports
2016125
2017255
2018529
2019589
2020878
2021704
2022759
2023743
20241,856
2025541
2026409

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,771 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
no adverse eventSignal4727.46.82,637
constipationSignal4555.95.41,884
disease progressionSignal2165.24.6732
myalgiaSignal2123.63.1389
peripheral swellingSignal1803.32.9293
weight increasedSignal2132.72.4230
deathSignal7182.42.2593
fatigue5261.91.8241
rash2671.71.686
off label use4721.51.491
asthenia2001.51.335
dyspnoea2401.21.19
pain1630.80.613
nausea1670.60.546
drug ineffective1730.40.3193

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.